North Charleston

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Asthma4 trials
• Obesity3 trials
• COPD2 trials
• Chronic rhinosinusitis with nasal polyps1 trial
• Heart failure1 trial
• Lung cancer1 trial
• Myasthenia gravis1 trial
• Prostate cancer1 trial
• Type 2 diabetes1 trial

Phase

• Phase 39 trials
• Phase 24 trials
• Phase 41 trial

Status

• Completed10 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• AstraZeneca13 trials
• Alexion Pharmaceuticals, Inc.1 trial
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics1 trial

Running trials

• Recruiting

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Aleniglipron Phase 2 Body Composition Study

  NCT07169942· Phase 2· Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics· Source

• Completed

  Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

  NCT06579092· Phase 2· AstraZeneca· Source

• Completed

  A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

  NCT06595238· Phase 2· AstraZeneca· Source

• Completed

  Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

  NCT06563102· Phase 4· AstraZeneca· Source

• Completed

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· Phase 3· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

  NCT04851964· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· AstraZeneca· Source

• Completed

  A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

  NCT04631016· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· AstraZeneca· Source

• Completed

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· AstraZeneca· Source